|
1
|
Kirkali Z and Tuzel E: Transitional cell
carcinoma of the ureter and renal pelvis. Crit Rev Oncol Hematol.
47:155–169. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Oosterlinck W, Solsona E, van der Meijden
AP, et al: EAU guidelines on diagnosis and treatment of upper
urinary tract transitional cell carcinoma. Eur Urol. 46:147–154.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Krogh J, Kvist E and Rye B: Transitional
cell carcinoma of the upper urinary tract: prognostic variables and
post-operative recurrences. Br J Urol. 67:32–36. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lehmann J, Suttmann H, Kovac I, et al:
Transitional cell carcinoma of the ureter: prognostic factors
influencing progression and survival. Eur Urol. 51:1281–1288. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sanderson KM, Cai J, Miranda G, Skinner DG
and Stein JP: Upper tract urothelial recurrence following radical
cystectomy for transitional cell carcinoma of the bladder: an
analysis of 1,069 patients with 10-year followup. J Urol.
177:2088–2094. 2007.PubMed/NCBI
|
|
6
|
Hall MC, Womack S, Sagalowsky AI, Carmody
T, Erickstad MD and Roehrborn CG: Prognostic factors, recurrence
and survival in transitional cell carcinoma of the upper urinary
tract: a 30-year experience in 252 patients. Urology. 52:594–601.
1998.PubMed/NCBI
|
|
7
|
Kang CH, Yu TJ, Hsieh HH, et al: The
development of bladder tumors and contralateral upper urinary tract
tumors after primary transitional cell carcinoma of the upper
urinary tract. Cancer. 98:1620–1626. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zigeuner RE, Hutterer G, Chromecki T,
Rehak P and Langner C: Bladder tumour development after urothelial
carcinoma of the upper urinary tract is related to primary tumour
location. BJU Int. 98:1181–1186. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Catto JW, Yates DR, Rehman I, et al:
Behavior of urothelial carcinoma with respect to anatomical
location. J Urol. 177:1715–1720. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Catto JW, Azzouzi AR, Amira N, et al:
Distinct patterns of microsatellite instability are seen in tumours
of the urinary tract. Oncogene. 22:8699–8706. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Munoz JJ and Ellison LM: Upper tract
urothelial neoplasms: incidence and survival during the last 2
decades. J Urol. 164:1523–1525. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zigeuner R and Pummer K: Urothelial
carcinoma of the upper urinary tract: surgical approach and
prognostic factors. Eur Urol. 53:720–731. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Turkeri LN: Neo/adjuvant therapy in upper
tract urothelial carcinoma. Eur Urol Suppl. 6:549–554. 2007.
View Article : Google Scholar
|
|
14
|
Seaman EK, Slawin KM and Benson MC:
Treatment options for upper tract transitional-cell carcinoma. Urol
Clin North Am. 20:349–354. 1993.PubMed/NCBI
|
|
15
|
Miyamoto H, Yang Z, Chen YT, et al:
Promotion of bladder cancer development and progression by androgen
receptor signals. J Natl Cancer Inst. 99:558–568. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Noronha RF and Rao BR: Sex hormone
receptors in localized and advanced transitional cell carcinoma of
urinary tract in humans. Urology. 28:401–403. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Boorjian S, Ugras S, Mongan NP, et al:
Androgen receptor expression is inversely correlated with
pathologic tumor stage in bladder cancer. Urology. 64:383–388.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tuygun C, Kankaya D, Imamoglu A, et al:
Sex-specific hormone receptors in urothelial carcinomas of the
human urinary bladder: a comparative analysis of
clinicopathological features and survival outcomes according to
receptor expression. Urol Oncol. 29:43–51. 2011. View Article : Google Scholar
|
|
19
|
Imada S, Akaza H, Ami Y, Koiso K, Ideyama
Y and Takenaka T: Promoting effects and mechanisms of action of
androgen in bladder carcinogenesis in male rats. Eur Urol.
31:360–364. 1997.PubMed/NCBI
|
|
20
|
Wu JT, Han BM, Yu SQ, Wang HP and Xia SJ:
Androgen receptor is a potential therapeutic target for bladder
cancer. Urology. 75:820–827. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shyr CR, Chen CC, Hsieh TF, et al: The
expression and actions of androgen receptor in upper urinary tract
urothelial carcinoma (UUTUC) tissues and the primary cultured
cells. Endocrine. 43:191–199. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tzeng CC, Liu HS, Li C, et al:
Characterization of two urothelium cancer cell lines derived from a
blackfoot disease endemic area in Taiwan. Anticancer Res.
16:1797–1804. 1996.PubMed/NCBI
|
|
23
|
Soga N, Arima K and Sugimura Y: Adjuvant
methotrexate, vinblastine, adriamycin and cisplatin chemotherapy
has potential to prevent recurrence of bladder tumors after
surgical removal of upper urinary tract transitional cell
carcinoma. Int J Urol. 15:800–803. 2008. View Article : Google Scholar
|
|
24
|
Kwak C, Lee SE, Jeong IG and Ku JH:
Adjuvant systemic chemotherapy in the treatment of patients with
invasive transitional cell carcinoma of the upper urinary tract.
Urology. 68:53–57. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
O’Donoghue JP and Crew JP: Adjuvant
topical treatment of upper urinary tract urothelial tumours. BJU
Int. 94:483–485. 2004.PubMed/NCBI
|
|
26
|
Robey R, Polgar O, Deeken J, To K and
Bates S: ABCG2: determining its relevance in clinical drug
resistance. Cancer Metastasis Rev. 26:39–57. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lai JJ, Lai KP, Chuang KH, et al:
Monocyte/macrophage androgen receptor suppresses cutaneous wound
healing in mice by enhancing local TNF-alpha expression. J Clin
Invest. 119:3739–3751. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ma WL, Hsu CL, Wu MH, et al: Androgen
receptor is a new potential therapeutic target for the treatment of
hepatocellular carcinoma. Gastroenterology. 135:947–955. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wu MH, Ma WL, Hsu CL, et al: Androgen
receptor promotes hepatitis B virus-induced hepatocarcinogenesis
through modulation of hepatitis B virus RNA transcription. Sci
Transl Med. 2:32–35. 2010.PubMed/NCBI
|
|
30
|
Yang Z, Chang YJ, Yu IC, et al: ASC-J9
ameliorates spinal and bulbar muscular atrophy phenotype via
degradation of androgen receptor. Nat Med. 13:348–353. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mir C, Shariat SF, van der Kwast TH, et
al: Loss of androgen receptor expression is not associated with
pathological stage, grade, gender or outcome in bladder cancer: a
large multi-institutional study. BJU Int. 108:24–30. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
See WA: Continuous antegrade infusion of
adriamycin as adjuvant therapy for upper tract urothelial
malignancies. Urology. 56:216–222. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Eastham JA and Huffman JL: Technique of
mitomycin C instillation in the treatment of upper urinary tract
urothelial tumors. J Urol. 150:324–325. 1993.PubMed/NCBI
|
|
34
|
Sakamoto N, Naito S, Kumazawa J, et al:
Prophylactic intravesical instillation of mitomycin C and cytosine
arabinoside for prevention of recurrent bladder tumors following
surgery for upper urinary tract tumors: A prospective randomized
study. Int J Urol. 8:212–216. 2001. View Article : Google Scholar
|
|
35
|
Hoffmeyer S, Burk O, von Richter O, et al:
Functional polymorphisms of the human multidrug-resistance gene:
multiple sequence variations and correlation of one allele with
P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci
USA. 97:3473–3478. 2000. View Article : Google Scholar
|
|
36
|
Longley DB and Johnston PG: Molecular
mechanisms of drug resistance. J Pathol. 205:275–292. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Szakacs G, Paterson JK, Ludwig JA,
Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in
cancer. Nat Rev Drug Discov. 5:219–234. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Heinlein CA and Chang C: Androgen receptor
in prostate cancer. Endocr Rev. 25:276–308. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kang HY, Cho CL, Huang KL, et al:
Nongenomic androgen activation of phosphatidylinositol 3-kinase/Akt
signaling pathway in MC3T3-E1 osteoblasts. J Bone Miner Res.
19:1181–1190. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Song G, Ouyang G and Bao S: The activation
of Akt/PKB signaling pathway and cell survival. J Cell Mol Med.
9:59–71. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kennedy SG, Wagner AJ, Conzen SD, et al:
The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic
signal. Genes Dev. 11:701–713. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Scher HI and Sawyers CL: Biology of
progressive, castration-resistant prostate cancer: Directed
therapies targeting the androgen-receptor signaling axis. J Clin
Oncol. 23:8253–8261. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Niu Y, Chang TM, Yeh S, Ma WL, Wang YZ and
Chang C: Differential androgen receptor signals in different cells
explain why androgen-deprivation therapy of prostate cancer fails.
Oncogene. 29:3593–3604. 2010. View Article : Google Scholar : PubMed/NCBI
|
